Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramsay, R. E.
Right arrow Articles by DeToledo, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ramsay, R. E.
Right arrow Articles by DeToledo, J.
NEUROLOGY 1996;46:17S-19S
© 1996 American Academy of Neurology

Intravenous administration of fosphenytoin

Options for the management of seizures

R. Eugene Ramsay, MD and John DeToledo, MD

From the Departments of Neurology (Drs. Ramsay and DeToledo) and Psychiatry (Dr. Ramsay) and the International Center for Epilepsy (Drs. Ramsay and DeToledo), University of Miami, FL.
Address correspondence and reprint requests to Dr. R. Eugene Ramsay, 10135 SW 79th Avenue, Miami, FL 33156.

Abstract.

Fosphenytoin is a water-soluble disodium phosphate ester of phenytoin that is converted in plasma to phenytoin. Fosphenytoin is compatible with most common IV solutions and can be administered safely through the IM route. An additional safety factor is the absence of propylene glycol in the fosphenytoin formulation. Propylene glycol is used as a vehicle in the IV phenytoin preparation and by itself may produce serious cardiovascular complications. Studies of the pharmacokinetics, safety, and tolerance of IV fosphenytoin have demonstrated that fosphenytoin produces phenytoin plasma concentrations similar to those achieved with oral and IV phenytoin, but without significant cardiovascular effects and only minimal discomfort at the injection site. Aside from local reactions, the most common adverse events associated with fosphenytoin have been pruritus and reactions typical of phenytoin (e.g., dizziness, somnolence, and ataxia). Fosphenytoin represents a significant advance in the treatment of patients with seizures who require parenteral therapy.

NEUROLOGY 1996;46(Suppl 1): S17-S19






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by AAN Enterprises, Inc.